Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(fenofibrate)
3,764 results
  • StatPearls: Fenofibrate [BOOK]
    . StatPearls Publishing: Treasure Island (FL) Sidhu Gursharan G Avalon University School of Medicine Tripp Jayson J CUSOM/Cape Fear Valley Health Center BOOK
  • Fenofibrate is FDA approved for the management and treatment of hypertriglyceridemia, primary hypercholesterolemia or mixed dyslipidemia. It reduces low-density lipoprotein, triglycerides, and total cholesterol while increasing high-density lipoprotein cholesterol in adults. Fenofibrate should be used in conjunction with a restriction of cholesterol intake and exercise if lifestyle modifications …
  • Preparation and Characterization of Fenofibrate-Loaded PVP Electrospun Microfibrous Sheets. [Journal Article]
    Pharmaceutics. 2020 Jun 30; 12(7)Sipos E, Csatári T, … Zelkó R
  • Fenofibrate-loaded electrospun microfibrous sheets were prepared in an attempt to enhance the dissolution of the poorly soluble antihyperlipidemic agent and to improve its bioavailability. Physicochemical changes that appeared during the electrospinning process were monitored using a wide array of solid-state characterization techniques, including attenuated total reflectance Fourier-transformed …
  • MiR-21 promotes calcium oxalate-induced renal tubular cell injury by targeting PPARA. [Journal Article]
    Am J Physiol Renal Physiol. 2020 Jul 06 [Online ahead of print]Su B, Han H, … Li J
  • Kidney stone disease is a crystal concretion formed in kidneys which has been associated with an increased risk of chronic kidney disease. MicroRNAs are functionally involved in kidney injury. Data mining using a microRNA array database suggested that miR-21 may be associated with calcium oxalate monohydrate (COM)-induced renal tubular cell injury. Here, we confirmed that COM exposure significant…
  • PPARα activation directly upregulates thrombomodulin in the diabetic retina. [Journal Article]
    Sci Rep. 2020 Jul 02; 10(1):10837.Shiono A, Sasaki H, … Takagi H
  • Two large clinical studies showed that fenofibrate, a commonly used peroxisome proliferator-activated receptor α (PPARα) agonist, has protective effects against diabetic retinopathy. However, the underlying mechanism has not been clarified. We performed genome-wide analyses of gene expression and PPARα binding sites in vascular endothelial cells treated with the selective PPARα modulator pemafibr…
  • Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists. [Journal Article]
    Cell Biol Toxicol. 2020 Jul 01 [Online ahead of print]Boeckmans J, Natale A, … Rodrigues RM
  • Non-alcoholic steatohepatitis (NASH) is a highly prevalent, chronic liver disease characterized by hepatic lipid accumulation, inflammation, and concomitant fibrosis. Up to date, no anti-NASH drugs have been approved. In this study, we reproduced key NASH characteristics in vitro by exposing primary human hepatocytes (PHH), human skin stem cell-derived hepatic cells (hSKP-HPC), HepaRG and HepG2 c…
  • Fenofibrate-induced renal dysfunction, yes or no? [Review]
    J Res Med Sci. 2020; 25:39.Emami F, Hariri A, … Nematbakhsh M
  • In the treatment process of hypertriglyceridemia and diabetic nephropathy in type 2 diabetes, fenofibrate (FEN) is a well-known medication. FEN is from fibrate class drugs that using orally; however, as a side effect, it is associated with serum creatinine level increasing. The aim of this review was to determine the real effect of FEN therapy on renal functions based on both experimental and cli…
  • Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment. [Case Reports]
    Case Rep Med. 2020; 2020:6865190.Buschard K, Holm LJ, Feldt-Rasmussen U
  • A 19-year-old girl was diagnosed with type 1 diabetes and showing polydipsia and polyuria. She was double autoantibody-positive and had a diabetes-prone tissue type. She was immediately started on insulin. Fenofibrate treatment (160 mg daily) was initiated seven days after diagnosis. The need for insulin quickly declined, and she took her last dose of insulin 19 days after the first dose of fenof…
  • Suitability of Artificial Membranes in Lipolysis-Permeation Assays of Oral Lipid-Based Formulations. [Journal Article]
    Pharm Res. 2020 May 20; 37(6):99.Hedge OJ, Bergström CAS
  • CONCLUSIONS: The LiDo membrane was able to withstand lipolysis for a sufficient assay period. However, the assay with porcine pancreatin as digestive agent did not predict the in vivo ranking of the assayed formulations better than existing methods. Comparison with a Caco-2 based assay method nonetheless indicates that the in vitro in vivo relationship of this cell-free model could be improved with alternative digestive agents.
  • Amyloid-beta (Aβ1-42)-induced paralysis in Caenorhabditis elegans is reduced through NHR-49/PPARalpha. [Journal Article]
    Neurosci Lett. 2020 Jun 21; 730:135042.Leiteritz A, Baumanns S, Wenzel U
  • Alzheimer´s disease is a neurodegenerative disorder characterized by the misfolding and aggregation of amyloid β (Aβ). Agonists of peroxisomal proliferator-activated receptors (PPARs) are discussed as anti-amyloidogenic compounds, e.g. due to their cholesterol-lowering activities. In a previous study we have shown in Caenorhabditis elegans expressing human Aβ in muscle cells, that inhibition of s…
  • Solubility of Pharmaceutical Ingredients in Natural Edible Oils. [Journal Article]
    Mol Pharm. 2020 May 15 [Online ahead of print]Brinkmann J, Rest F, … Sadowski G
  • Natural edible oils (NEOs) are common excipients for lipid-based formulations. Many of them are complex mixtures comprising hundreds of different triglycerides (TGs). One major challenge in developing lipid-based formulations is the variety in NEO compositions affecting the solubility of active pharmaceutical ingredients. In this work, solubilities of indomethacin (IND), ibuprofen (IBU), and feno…
New Search Next